β-catenin mRNA silencing and MEK inhibition display synergistic efficacy in preclinical tumor models

Colorectal carcinomas (CRC) harbor well-defined genetic abnormalities including aberrant activation of Wnt/β-catenin and MAPK pathways, often simultaneously. While the MAPK pathway can be targeted using potent small molecule drugs, including BRAF and MEK inhibitors, β-catenin inhibition has been his...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Cancer Ther
Päätekijät: Ganesh, Shanthi, Shui, Xue, Craig, Kevin P., Koser, Martin L., Chopda, Girish R., Cyr, Wendy A., Lai, Chengjung, Dudek, Henryk, Wang, Weimin, Brown, Bob D., Abrams, Marc T.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805618/
https://ncbi.nlm.nih.gov/pubmed/29282298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0605
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia